Cargando…

Feasibility and prognostic benefit of induction chemoradiotherapy followed by surgery in patients with locally advanced non-small cell lung cancer

BACKGROUND: The optimal treatment for patients with resectable non-small cell lung cancer (NSCLC) involving adjacent organs (T3 or T4) and/or cN2 remains unclear. We investigated whether or not induction chemoradiotherapy (ICRT) followed by surgery improves the survival. METHODS: We retrospectively...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanahashi, Masayuki, Niwa, Hiroshi, Yukiue, Haruhiro, Suzuki, Eriko, Yoshii, Naoko, Watanabe, Takuya, Kaminuma, Yasunori, Chiba, Kensuke, Tsuchida, Hiroyuki, Yobita, Shogo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330299/
https://www.ncbi.nlm.nih.gov/pubmed/32642172
http://dx.doi.org/10.21037/jtd.2020.03.17
_version_ 1783553088092635136
author Tanahashi, Masayuki
Niwa, Hiroshi
Yukiue, Haruhiro
Suzuki, Eriko
Yoshii, Naoko
Watanabe, Takuya
Kaminuma, Yasunori
Chiba, Kensuke
Tsuchida, Hiroyuki
Yobita, Shogo
author_facet Tanahashi, Masayuki
Niwa, Hiroshi
Yukiue, Haruhiro
Suzuki, Eriko
Yoshii, Naoko
Watanabe, Takuya
Kaminuma, Yasunori
Chiba, Kensuke
Tsuchida, Hiroyuki
Yobita, Shogo
author_sort Tanahashi, Masayuki
collection PubMed
description BACKGROUND: The optimal treatment for patients with resectable non-small cell lung cancer (NSCLC) involving adjacent organs (T3 or T4) and/or cN2 remains unclear. We investigated whether or not induction chemoradiotherapy (ICRT) followed by surgery improves the survival. METHODS: We retrospectively analyzed 84 patients with NSCLC involving the adjacent organs and/or cN2 who underwent ICRT followed by surgery at our hospital from 2006 to 2018. Presurgical treatment consisted of 2 courses of platinum-doublet and concurrent radiotherapy (40–50 Gy) to the tumor and involved field. RESULTS: All 84 patients completed ICRT. One patient died after completion of ICRT due to bacterial pneumonia. Radiological responses to ICRT were a complete response (CR), n=1; partial response (PR), n=48; stable disease (SD), n=32; and progressive disease (PD), n=2 (overall response rate: 58.3%). Eighty-one patients underwent radical surgery. The procedures included lobectomy, n=66; bilobectomy, n=7; pneumonectomy, n=6; and segmentectomy, n=2 (including 49 extended resections). Seventy-three patients (90%) underwent complete resection. The postoperative morbidity rate was 30%. The 30- and 90-day mortality rates were 1.2% and 2.4%, respectively. A pathological CR (Ef3) and major response (Ef2) were achieved in 17 (21.0%) and 38 (46.9%) patients, respectively; a minor response (Ef1) was observed in 26 (32%). The 5-year overall survival (OS) and recurrence-free survival (RFS) rates were 58.0% and 45.6%, respectively. The median survival time was 73.2 months. Based on the response to ICRT, patients with radiological CR or PR showed better 5-year OS than those with SD (63.7% vs. 40.0%, P=0.020). Patients with Ef3 or Ef2 demonstrated a much better 5-year OS than those with Ef1 (65.0% vs. 24.4%, P=0.005). CONCLUSIONS: ICRT followed by surgery for patients with NSCLC involving the adjacent organs and/or cN2 was feasible and improved the survival. A CR/PR or Ef2/Ef3 after ICRT led to a better prognosis.
format Online
Article
Text
id pubmed-7330299
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-73302992020-07-07 Feasibility and prognostic benefit of induction chemoradiotherapy followed by surgery in patients with locally advanced non-small cell lung cancer Tanahashi, Masayuki Niwa, Hiroshi Yukiue, Haruhiro Suzuki, Eriko Yoshii, Naoko Watanabe, Takuya Kaminuma, Yasunori Chiba, Kensuke Tsuchida, Hiroyuki Yobita, Shogo J Thorac Dis Original Article BACKGROUND: The optimal treatment for patients with resectable non-small cell lung cancer (NSCLC) involving adjacent organs (T3 or T4) and/or cN2 remains unclear. We investigated whether or not induction chemoradiotherapy (ICRT) followed by surgery improves the survival. METHODS: We retrospectively analyzed 84 patients with NSCLC involving the adjacent organs and/or cN2 who underwent ICRT followed by surgery at our hospital from 2006 to 2018. Presurgical treatment consisted of 2 courses of platinum-doublet and concurrent radiotherapy (40–50 Gy) to the tumor and involved field. RESULTS: All 84 patients completed ICRT. One patient died after completion of ICRT due to bacterial pneumonia. Radiological responses to ICRT were a complete response (CR), n=1; partial response (PR), n=48; stable disease (SD), n=32; and progressive disease (PD), n=2 (overall response rate: 58.3%). Eighty-one patients underwent radical surgery. The procedures included lobectomy, n=66; bilobectomy, n=7; pneumonectomy, n=6; and segmentectomy, n=2 (including 49 extended resections). Seventy-three patients (90%) underwent complete resection. The postoperative morbidity rate was 30%. The 30- and 90-day mortality rates were 1.2% and 2.4%, respectively. A pathological CR (Ef3) and major response (Ef2) were achieved in 17 (21.0%) and 38 (46.9%) patients, respectively; a minor response (Ef1) was observed in 26 (32%). The 5-year overall survival (OS) and recurrence-free survival (RFS) rates were 58.0% and 45.6%, respectively. The median survival time was 73.2 months. Based on the response to ICRT, patients with radiological CR or PR showed better 5-year OS than those with SD (63.7% vs. 40.0%, P=0.020). Patients with Ef3 or Ef2 demonstrated a much better 5-year OS than those with Ef1 (65.0% vs. 24.4%, P=0.005). CONCLUSIONS: ICRT followed by surgery for patients with NSCLC involving the adjacent organs and/or cN2 was feasible and improved the survival. A CR/PR or Ef2/Ef3 after ICRT led to a better prognosis. AME Publishing Company 2020-05 /pmc/articles/PMC7330299/ /pubmed/32642172 http://dx.doi.org/10.21037/jtd.2020.03.17 Text en 2020 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Tanahashi, Masayuki
Niwa, Hiroshi
Yukiue, Haruhiro
Suzuki, Eriko
Yoshii, Naoko
Watanabe, Takuya
Kaminuma, Yasunori
Chiba, Kensuke
Tsuchida, Hiroyuki
Yobita, Shogo
Feasibility and prognostic benefit of induction chemoradiotherapy followed by surgery in patients with locally advanced non-small cell lung cancer
title Feasibility and prognostic benefit of induction chemoradiotherapy followed by surgery in patients with locally advanced non-small cell lung cancer
title_full Feasibility and prognostic benefit of induction chemoradiotherapy followed by surgery in patients with locally advanced non-small cell lung cancer
title_fullStr Feasibility and prognostic benefit of induction chemoradiotherapy followed by surgery in patients with locally advanced non-small cell lung cancer
title_full_unstemmed Feasibility and prognostic benefit of induction chemoradiotherapy followed by surgery in patients with locally advanced non-small cell lung cancer
title_short Feasibility and prognostic benefit of induction chemoradiotherapy followed by surgery in patients with locally advanced non-small cell lung cancer
title_sort feasibility and prognostic benefit of induction chemoradiotherapy followed by surgery in patients with locally advanced non-small cell lung cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330299/
https://www.ncbi.nlm.nih.gov/pubmed/32642172
http://dx.doi.org/10.21037/jtd.2020.03.17
work_keys_str_mv AT tanahashimasayuki feasibilityandprognosticbenefitofinductionchemoradiotherapyfollowedbysurgeryinpatientswithlocallyadvancednonsmallcelllungcancer
AT niwahiroshi feasibilityandprognosticbenefitofinductionchemoradiotherapyfollowedbysurgeryinpatientswithlocallyadvancednonsmallcelllungcancer
AT yukiueharuhiro feasibilityandprognosticbenefitofinductionchemoradiotherapyfollowedbysurgeryinpatientswithlocallyadvancednonsmallcelllungcancer
AT suzukieriko feasibilityandprognosticbenefitofinductionchemoradiotherapyfollowedbysurgeryinpatientswithlocallyadvancednonsmallcelllungcancer
AT yoshiinaoko feasibilityandprognosticbenefitofinductionchemoradiotherapyfollowedbysurgeryinpatientswithlocallyadvancednonsmallcelllungcancer
AT watanabetakuya feasibilityandprognosticbenefitofinductionchemoradiotherapyfollowedbysurgeryinpatientswithlocallyadvancednonsmallcelllungcancer
AT kaminumayasunori feasibilityandprognosticbenefitofinductionchemoradiotherapyfollowedbysurgeryinpatientswithlocallyadvancednonsmallcelllungcancer
AT chibakensuke feasibilityandprognosticbenefitofinductionchemoradiotherapyfollowedbysurgeryinpatientswithlocallyadvancednonsmallcelllungcancer
AT tsuchidahiroyuki feasibilityandprognosticbenefitofinductionchemoradiotherapyfollowedbysurgeryinpatientswithlocallyadvancednonsmallcelllungcancer
AT yobitashogo feasibilityandprognosticbenefitofinductionchemoradiotherapyfollowedbysurgeryinpatientswithlocallyadvancednonsmallcelllungcancer